Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
American Society of Clinical Oncology (ASCO)
American Society of Clinical Oncology (ASCO)
The
American Society of Clinical Oncology
(
ASCO
) is a professional organization representing physicians of all oncology sub-specialties who care for people with cancer. Founded in 1964 by Fred Ansfield, Harry Bisel, Herman Freckman, Arnoldus Goudsmit, Robert Talley, William Wilson, and Jane C. Wright, it has nearly 45,000 members worldwide.
Anti-HER2/HER3 αDC1 Vaccines Plus Pembrolizumab for Brain Metastasis in Triple-Negative or HER2-Positive BC
ASCO 2023 - Breast Cancer
An ongoing phase 2 study is evaluating HER2/HER3-directed dendritic cell vaccines combined with pembrolizumab in patients with brain metastasis from triple-negative breast cancer or HER2-positive breast cancer.
Read More ›
Neoadjuvant Intratumoral Dendritic Cell Vaccine Therapy Plus Paclitaxel, Trastuzumab, and Pertuzumab in HER2-Positive BC
ASCO 2023 - Breast Cancer
Preliminary results of the phase 2 NATASHA trial showed that neoadjuvant HER2-directed intratumoral dendritic cell vaccine therapy followed by paclitaxel, trastuzumab, and pertuzumab was well-tolerated in patients with HER2-positive breast cancer.
Read More ›
Phase 1b/2 Trial of Ribociclib, Tucatinib, and Trastuzumab for HER2-Positive BC
ASCO 2023 - Breast Cancer
The phase 1b/2 UCLA B-13 trial is evaluating the safety and efficacy of HER2 tyrosine kinase inhibitor tucatinib plus the cyclin-dependent kinase 4/6 inhibitor ribociclib and trastuzumab in the neoadjuvant setting for the treatment of patients with HER2-positive breast cancer.
Read More ›
Dalpiciclib Combined With Pyrotinib and Endocrine Therapy in Dual Receptor–Positive (ER-Positive/HER2-Positive) MBC
ASCO 2023 - Breast Cancer
Results of the phase 2 PLEASURABLE study indicated that the chemotherapy-sparing regimen of dalpiciclib combined with pyrotinib and endocrine therapy showed significant antitumor activity for patients with estrogen receptor–positive/HER2-positive metastatic breast cancer in the front-line setting.
Read More ›
Preclinical and Early Clinical Data of the HER2 Inhibitor ZN-1041 in Patients With BC With Brain Metastases
ASCO 2023 - Breast Cancer
Promising safety and antitumor activity data were obtained with the HER2 inhibitor ZN-1041, which is specifically designed to cross the blood-brain barrier, in preclinical and phase 1 studies in patients with HER2-positive breast cancer with brain metastases.
Read More ›
First-Line Zanidatamab Plus Docetaxel in Advanced HER2-Positive BC
ASCO 2023 - Breast Cancer
Updated results of a phase 1b/2 trial showed that zanidatamab plus docetaxel as first-line therapy had a manageable safety profile and demonstrated promising antitumor activity in patients with advanced HER2-positive breast cancer.
Read More ›
Real-World Treatment Patterns of Tucatinib Therapy in HER2-Positive MBC
ASCO 2023 - Breast Cancer
Real-world data from a US claims database reported similar efficacy as from a previous clinical trial in patients with previously treated HER2-positive metastatic breast cancer.
Read More ›
Anti-HER2 Antibody Inetetamab Plus Camrelizumab and Utidelone for Pretreated HER2-Positive MBC
ASCO 2023 - Breast Cancer
Final results of the phase 2 ICU trial confirmed earlier reports of promising efficacy and acceptable safety of anti-HER2 antibody inetetamab in combination with camrelizumab and utidelone in patients with pretreated HER2-positive metastatic breast cancer.
Read More ›
Dalpiciclib and Pyrotinib in HER2-Positive Advanced BC: Phase 2 DAP-HER-01
ASCO 2023 - Breast Cancer
Updated results of the DAP-HER-01 trial continue to show promising efficacy and manageable toxicity with the oral chemotherapy-free dalpiciclib plus pyrotinib in patients with HER2-positive advanced breast cancer, including the difficult-to-treat subgroups of hormone receptor–negative disease or brain metastases.
Read More ›
Neratinib Plus T-DM1 for HER2-Positive BC With Molecular Residual Disease
ASCO 2023 - Breast Cancer
The phase 2 KAN-HER2 MRD trial will evaluate the addition of neratinib to standard trastuzumab emtansine in patients with HER2-positive breast cancer and evidence of molecular residual disease.
Read More ›
Page 1 of 29
1
2
3
4
5
6
7
8
9
10
Conference Correspondent Coverage is Brought to You by the Publishers of:
Learn more about our family of publications.
View Our Publications
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us